Advanced search
Combine gene, variant, phenotype, region and year filters
Every result shows the extracted entities next to the sentences that support them; rows for the searched entities come first.
Transparent by designEvery result links extracted entities to its source sentence and publication identifier.
Knowledge-base search
About your search
CD33 and leukemia are reported together in 11 articles.
Gene
CD33
- HGNC
- HGNC:1659
17articles
17mentions
0variants with confirmed gene link
Most co-reported phenotypes (articles)
Phenotype
Leukemia
652articles
652mentions
12co-reported genes shown
Most co-reported genes (articles)
Counts are literature co-mentions in SaudiVarKB, not clinical or causal assertions. Gene details: HGNC; variant status: ClinVar via dbSNP.
Publications
11 records shown · first 60Understanding the Role of All-Trans Retinoic Acid in Acute Myeloid Leukemia Cells.
PMID 41208847 | PMCID PMC12591235 | DOI 10.14740/wjon2676 · World journal of oncology · 2025 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | CD33 | “Expression of myeloid and monocytic surface markers (CD38, CD45, CD11b, human leukocyte antigen (HLA)-DR, CD15, CD13, CD33) was analyzed in parallel with morphological assessment using Giemsa-stained cytospin preparations.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Understanding the Role of All-Trans Retinoic Acid in Acute Myeloid Leukemia Cells.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | CD38 | “Expression of myeloid and monocytic surface markers (CD38, CD45, CD11b, human leukocyte antigen (HLA)-DR, CD15, CD13, CD33) was analyzed in parallel with morphological assessment using Giemsa-stained cytospin preparations.” | 0.98 | hgnc_dict_v1 |
| gene | RUNX1 | “In addition, the mRNA expression of myeloid-specific transcription factors PU.1, RUNX1 and CEBPα was evaluated following ATRA treatment.” | 0.98 | hgnc_dict_v1 |
Exploring the interplay between microRNA expression and DNA mutation analysis in AML patients.
PMID 38831894 | PMCID PMC11145380 | DOI 10.1016/j.sjbs.2024.104027 · Saudi journal of biological sciences · 2024 · 11 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | CD33 | “Cell surface protein expression analysis revealed upregulation of CD45, CD99, CD34, HLA-DR, CD38, CD13, CD33, MPO, CD15 and CD117 in AML patients.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Exploring the interplay between microRNA expression and DNA mutation analysis in AML patients.” | 0.93 | phenotype_alias_lexicon_v2 |
| gene | CD99 | “Cell surface protein expression analysis revealed upregulation of CD45, CD99, CD34, HLA-DR, CD38, CD13, CD33, MPO, CD15 and CD117 in AML patients.” | 0.98 | hgnc_dict_v1 |
| gene | CD34 | “Cell surface protein expression analysis revealed upregulation of CD45, CD99, CD34, HLA-DR, CD38, CD13, CD33, MPO, CD15 and CD117 in AML patients.” | 0.98 | hgnc_dict_v1 |
A rare presentation of BCR-ABL1 and RUNX1-MECOM rearrangement in a pediatric patient with acute myeloid leukemia.
PMID 38751957 | PMCID PMC11093904 | DOI 10.1002/ccr3.8917 · Clinical case reports · 2024 · 6 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | CD33 | “Bone marrow was hypercellular with 71% blasts, and flow cytometry showed myeloid markers including CD11c, CD33, CD34, and CD45 among others indicating AML with monocytic differentiation.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “A rare presentation of BCR-ABL1 and RUNX1-MECOM rearrangement in a pediatric patient with acute myeloid leukemia.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | ABL1 | “KEY CLINICAL MESSAGE: In a patient with de novo AML, co-existing BCR::ABL1 p190 isoform and RUNX1::MECOM rearrangement is accompanied by a very poor prognosis including limited response to treatment and no molecular remission.” | 0.98 | hgnc_dict_v1 |
| gene | RUNX1 | “KEY CLINICAL MESSAGE: In a patient with de novo AML, co-existing BCR::ABL1 p190 isoform and RUNX1::MECOM rearrangement is accompanied by a very poor prognosis including limited response to treatment and no molecular remission.” | 0.98 | hgnc_dict_v1 |
De novo lymphoid blastic phase chronic myeloid leukemia: report and contemporary discussion.
PMID 36448578 | DOI 10.1080/16078454.2022.2150386 · Hematology (Amsterdam, Netherlands) · 2022 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | CD33 | “Flowcytometry was consistent with B-ALL, with aberrant expression of CD13 and CD33.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “De novo lymphoid blastic phase chronic myeloid leukemia: report and contemporary discussion.” | 0.98 | phenotype_alias_lexicon_v2 |
T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments.
PMID 33953290 | PMCID PMC8257483 | DOI 10.1038/s41375-021-01253-x · Leukemia · 2021 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | CD33 | “These include bispecific and dual antigen receptor-targeting antibodies (targeted to CD33, CD123, CLL-1, and others), chimeric antigen receptor (CAR) T-cell therapies, and T-cell immune checkpoint inhibitors (including those targeting PD-1, PD-L1, CTLA-4, and newer targets such as TIM3 and STING).” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments.” | 0.98 | phenotype_alias_lexicon_v2 |
Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy.
PMID 31115909 | DOI 10.1111/bjh.15960 · British journal of haematology · 2019 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | CD33 | “Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy.” | 0.93 | phenotype_alias_lexicon_v2 |
| gene | CD2 | “Excepting definitional markers, there was a significant differential expression of the markers CD2, CD10, CD33 and TdT between ETP-ALL and non-ETP-ALL.” | 0.98 | hgnc_dict_v1 |
| phenotype | lymphoma | “Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy.” | 0.98 | phenotype_alias_lexicon_v2 |
Effects of plant-derived anti-leukemic drugs on individualized leukemic cell population profiles in Egyptian patients.
PMID 26870259 | PMCID PMC4727189 | DOI 10.3892/ol.2015.3916 · Oncology letters · 2016 · 6 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | CD33 | “An increased expression of LAIPs, including CD4, CD14, CD33 and CD34, was considered a surrogate marker of the desired response of leukemia cells to treatment with plant-derived drugs.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “The relationship between treatments with plant-derived drugs and leukemia-associated immunophenotypes (LAIPs) of clinically isolated leukemia cells has yet to be established.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | CD4 | “An increased expression of LAIPs, including CD4, CD14, CD33 and CD34, was considered a surrogate marker of the desired response of leukemia cells to treatment with plant-derived drugs.” | 0.98 | hgnc_dict_v1 |
| gene | CD14 | “An increased expression of LAIPs, including CD4, CD14, CD33 and CD34, was considered a surrogate marker of the desired response of leukemia cells to treatment with plant-derived drugs.” | 0.98 | hgnc_dict_v1 |
Simultaneous existence of acute myeloid leukemia and chronic lymphocytic leukemia: a case report.
PMID 27643996 | PMCID PMC5028963 | DOI 10.1186/s12885-016-2780-5 · BMC cancer · 2016 · 6 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | CD33 | “The immunologic phenotype of blasts was characterized by the co-expression of CD13, CD33, CD14, CD4, CD15, CD64, HLA-DR, CD11c.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Simultaneous existence of acute myeloid leukemia and chronic lymphocytic leukemia: a case report.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | CD14 | “The immunologic phenotype of blasts was characterized by the co-expression of CD13, CD33, CD14, CD4, CD15, CD64, HLA-DR, CD11c.” | 0.98 | hgnc_dict_v1 |
| gene | CD4 | “The immunologic phenotype of blasts was characterized by the co-expression of CD13, CD33, CD14, CD4, CD15, CD64, HLA-DR, CD11c.” | 0.98 | hgnc_dict_v1 |
Clinical significance of co-expression of aberrant antigens in acute leukemia: a retrospective cohort study in Makah Al Mukaramah, Saudi Arabia.
PMID 24528030 | DOI 10.7314/apjcp.2014.15.1.221 · Asian Pacific journal of cancer prevention : APJCP · 2014 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | CD33 | “In ALL cases, CD33 was expressed in 7/33 and CD13 in 5/33.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Clinical significance of co-expression of aberrant antigens in acute leukemia: a retrospective cohort study in Makah Al Mukaramah, Saudi Arabia.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | CD19 | “CD19 was detected in 4/40 AML associated with M2 and t (8; 21).” | 0.98 | hgnc_dict_v1 |
| population | Saudi Arabia | “Clinical significance of co-expression of aberrant antigens in acute leukemia: a retrospective cohort study in Makah Al Mukaramah, Saudi Arabia. MATERIALS AND METHODS: A total of 73 (40 AML and 33 ALL) newly diagnosed acute leukemia cases presenting to KAMC, Kingdom of Saudi Arabia, were included. Regarding T Ag in B-ALL CD2 was expressed in 2 cases and CD56 in 3 cases.” | 0.95 | saudi_context_rules_v1 |
TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow.
PMID 23940084 | DOI 10.1002/ajh.23567 · American journal of hematology · 2013 · 5 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | CD33 | “Other antigens expressed by subsets of BPDCN cases included the following: CD56 (13/15; 81%), CD33 (7/10; 70%), CD7 (11/14; 69%), TdT (5/15; 33%), CD2 (5/11; 31%), CD117 (2/9; 22%), and CD5 (2/13; 15%).” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Distinguishing blastic plasmacytoid dendritic cell neoplasm (BPDCN) from acute myeloid leukemia (AML) is gaining increased importance because of emerging differences in therapeutic approaches, and this distinction can be problematic in bone marrow specimens.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | TET2 | “TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow.” | 0.98 | hgnc_dict_v1 |
| gene | CD19 | “Immunophenotypic analysis showed that the neoplastic cells were positive for CD4, CD123, TCL-1, and HLA-DR and were negative for CD3, CD8, CD13, CD19, CD34, and myeloperoxidase.” | 0.98 | hgnc_dict_v1 |
Molecular detection of BCR/ABL fusion gene in Saudi acute lymphoblastic leukemia patients.
PMID 17496935 · Journal of the Egyptian National Cancer Institute · 2006 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | CD33 | “PATIENTS AND METHODS: Twenty newly diagnosed ALL patients, 16 adult and 4 paediatric cases, were included in the study, 11 cases (55%) were of precursor B phenotype, 8 cases (40%) belonged to T lineage, while one case was biphenotypic expressing mainly precursor B cell markers tether with CD13, CD33, CD117, Detection of BCR/ABL fusion gene was done using interphase FISH technique and was confirmed molecularly using the RT-PCR technique.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Molecular detection of BCR/ABL fusion gene in Saudi acute lymphoblastic leukemia patients.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | BCR | “Molecular detection of BCR/ABL fusion gene in Saudi acute lymphoblastic leukemia patients.” | 0.98 | hgnc_dict_v1 |
| population | Saudi Arabia | “Molecular detection of BCR/ABL fusion gene in Saudi acute lymphoblastic leukemia patients. PATIENTS AND METHODS: Twenty newly diagnosed ALL patients, 16 adult and 4 paediatric cases, were included in the study, 11 cases (55%) were of precursor B phenotype, 8 cases (40%) belonged to T lineage, while one case was biphenotypic expressing mainly precursor B cell markers tether with CD13, CD33, CD117, Detection of BCR/ABL fusion gene was done using interphase FISH technique and was confirmed molecularly using the RT-PCR technique.” | 0.95 | saudi_context_rules_v1 |